Guideline Summary for Diagnosis and Management of Severe Alcoholic Hepatitis with Cholestatic Features

Diagnostic Laboratory Criteria

An AST/ALT ratio greater than 4.5 (e.g., AST ≈ 165 U/L, ALT ≈ 36 U/L) is highly specific for alcohol‑related liver injury and exceeds the diagnostic threshold of >1.5 for alcoholic hepatitis. [1][2]
Transaminase levels remaining below 400 U/L are characteristic of alcoholic hepatitis and help differentiate it from drug‑induced or ischemic hepatitis, which typically show values >1,000 U/L. 2
A total bilirubin level above 3 mg/dL (e.g., ≈ 7 mg/dL) fulfills the bilirubin criterion for alcoholic hepatitis and signals significant hepatocellular dysfunction with cholestasis. [1][2]
Markedly elevated alkaline phosphatase (e.g., ≈ 461 U/L) indicates a prominent cholestatic component that can be present in severe alcoholic hepatitis with intra‑hepatic cholestasis. 1

A Maddrey Discriminant Function (mDF) ≥ 32 defines severe alcoholic hepatitis and is associated with a 30‑50 % 28‑day mortality if untreated. [1][2]
A Model for End‑Stage Liver Disease (MELD) score > 20‑21 denotes severe disease and predicts high 90‑day mortality. [1][2]
Elevated NT‑proBNP (e.g., ≈ 2,500 pg/mL) suggests circulatory dysfunction or systemic inflammatory response, which commonly accompanies severe alcoholic hepatitis. 1

Wilson disease should be excluded when the AST/ALT ratio exceeds 2.2 and bilirubin is elevated; an alkaline phosphatase‑to‑bilirubin ratio > 4 (e.g., 66) argues against Wilson disease. 3
Abdominal ultrasound or CT imaging is required to rule out extra‑hepatic biliary obstruction when alkaline phosphatase is markedly raised. 2
Comprehensive testing for viral hepatitis (HBsAg, anti‑HCV, HEV RNA), autoimmune hepatitis (ANA, anti‑smooth muscle antibodies, IgG), and a detailed medication/herbal product history is mandatory to exclude alternative etiologies. [3][2]

In Western cohorts, 30‑57 % of patients with severe alcoholic hepatitis develop ACLF, with a 28‑day mortality ranging from 31‑72 %. 3

Probable alcoholic hepatitis is diagnosed when heavy alcohol consumption within the prior 60 days (≥ 40 g/day for women) is confirmed and no confounding factors are present. 2
When confounding factors (e.g., atypical medications, uncertain alcohol history) exist, the case is classified as possible alcoholic hepatitis and liver biopsy is required for confirmation. 2
In the setting of coagulopathy or ascites, a transjugular liver biopsy is preferred over a percutaneous approach. 2
Biopsy should be strongly considered before initiating corticosteroid therapy in patients with mDF ≥ 32 or MELD > 20 to verify the diagnosis and exclude other causes. 2

Typical histology includes macrovesicular steatosis plus at least one of the following: neutrophil infiltration, hepatocyte ballooning, or Mallory‑Denk bodies; additional features may comprise cholestasis (bilirubinostasis), megamitochondria, and “chicken‑wire” fibrosis. [1][2]

Confirmation of recent heavy alcohol use (within 60 days) is essential; collateral history from family or caregivers should be obtained because patients often under‑report consumption. 2
A markedly elevated alkaline phosphatase, while possible in severe intra‑hepatic cholestasis, is atypical for uncomplicated alcoholic hepatitis and mandates imaging to exclude biliary obstruction or infiltrative disease. [1][3]
Prior to corticosteroid initiation, active infection (e.g., spontaneous bacterial peritonitis, pneumonia, urinary tract infection) must be excluded, as infection is an absolute contraindication. 1
Elevated NT‑proBNP may reflect circulatory dysfunction from systemic inflammation, alcohol‑related cardiomyopathy, or volume overload; echocardiographic assessment of ventricular function is recommended. 3